MD Anderson and Federation Bio Announce Collaboration to Develop Novel Microbiome Treatment for Patients with Immunotherapy-Resistant Cancers Read more
Cidara Therapeutics and WuXi XDC Expand Collaboration for IND-enabling CMC Development to Advance Cidara’s CD73 Oncology DFC Program Read more
Benlysta granted Orphan Drug Designation by US FDA for the potential treatment of systemic sclerosis Read more
Daewoong enters exclusive licensing agreement with CS Pharmaceuticals for Bersiporocin in Idiopathic Pulmonary Fibrosis in the Greater China Region Read more
uniQure and Apic Bio enter into global licensing agreement for APB-102, a clinical stage gene therapy for patients with ALS caused by mutations in SOD1 Read more
Ascletis Announces U.S. FDA Approval of Conducting a Phase IIa Clinical Trial for ASC10 to Treat Respiratory Syncytial Virus Infection Read more
Sun Pharma acquires Disperzyme and Phlogam brands to strengthen its anti-inflammatory portfolio Read more
Hillstream BioPharma Signs an Exclusive Option Agreement to Advance Next-Generation Anti-MUC1-C Agents for Drug Resistant Cancers Read more